What are the current understandings of the autoimmune processes in psoriatic arthritis? How do different DMARDs work to modify the disease course of psoriatic arthritis?

... psoriatic arthritis (PsA)1. CLINICAL DATA. IMPACT 2. ACR20 RESPONSE; Enthesitis; Dactylitis. At Week 14, significantly more patients receiving REMICADE® 5 mg/kg ... Jan 23, 2024 ... Background Information. Description. Psoriatic arthritis is a seronegative inflammatory spondyloarthropathy associated with mild to very severe ... SELECT-PsA 2 Biologic DMARD-IR Patient data for RINVOQ 15 mg: 58. In an As Observed (AO) analysis, patients with missing data ... Oct 22, 2024 ... This qualitative study explores the perspective of psoriatic arthritis (PsA) patients towards these so-called digital biomarkers (dBMs). Psoriatic Arthritis (PsA) · Systemic Lupus Erythematosus (SLE) · Sjögren's ... arthritis) that occur in all patients, regardless of diagnosis. These ... Nov 23, 2021 ... Therefore, skin involvement offers to the rheumatologist a unique opportunity to study PsA in a very early phase, having a cohort of psoriatic “ ... In KEEPsAKE-1, the study population had an inadequate response or intolerance to at least 1 csDMARD, while in KEEPsAKE-2, patients had an inadequate response or ... For patients ≥ 50 kg (at the time of dosing), the dose is 150 mg. (2.3). • Psoriatic Arthritis: Adult Patients. Subcutaneous Dosage: o For PsA patients with ... ... PsA symptoms like joint pain, swelling, and stiffness at 4 weeks. Those who continued the study found at least 50% reduction in PsA symptoms at 52 weeks. TREMFYA® is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections or pills (systemic ...